Abstract Library

#4235 Tricuspid valve replacement and liver transplantation in a 51-year-old female patient with grade 1 ileum NET and refractory carcinoid syndrome

Introduction: Refractory carcinoid syndrome (RCSy) could lead to severe complications.

Conference:

Presenting Author: Tőke J

Authors: Tőke J, Kövesdi A, Szolnoky J, Huszty G, Piros L,

Keywords: refractory carcinoid syndrome, liver transplantation, ileum neuroendocrine tumor,

#3504 Telotristat ethyl affects crosstalk between tumor cells and stromal fibroblasts in small intestinal neuroendocrine tumors (SI-NETs)

Introduction: SI-NETs are often associated with mesenteric fibrosis (MF) which causes significant morbidity and mortality. Telotristat ethyl (TE) was developed to treat carcinoid syndrome in SI-NET patients however, recent studies indicated TE could also have anti-tumor activity, the mechanism for which remains unclear.

Conference:

Presenting Author:

Authors: Hodgetts H, Martins M, Chen L, Laskaratos F, Hall A,

Keywords: fibrosis, fibroblast, crosstalk, telotristat, intestine, small, tumor,

#3301 Telotristat in the management of carcinoid diarrhoea - Real world experience of patients from an ENETS Centre of Excellence in neuroendocrine tumors

Introduction: Carcinoid syndrome occurs in 20% patients, presenting with flushing, abdominal pain, diarrhoea, and wheeze. The standard of care for carcinoid syndrome is somatostatin analogues (SSAs) with add-on Creon, codeine and loperamide therapy. Nonetheless, half of patients experience debilitating diarrhoea. Telotristat-ethyl is a peripheral tryptophan-hydroxylase inhibitor approved for treatment of diarrhoea, supported by Phase-3 clinical trials.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Cianci N

Authors: Khanna A, Cianci N, Shah H, Chauhan J, Pipe M,

Keywords: Telotristat, carcinoid syndrome, somatostatin analogues, neuroendocrine tumor,

#3290 Intratumoral serotonin might decrease the efficacy of PRRT in ileal neuroendocrine tumors

Introduction: Partial remission can be achieved by peptide receptor radionuclide therapy (PRRT) in only roughly 20% of patients with midgut neuroendocrine tumor (NET). This low remission rate can be due to the radioprotective role of stored intracytoplasmic serotonin in NET cells. If blocked, e.g. by telotristatethyl, PRRT efficacy might be increased.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Prasad V

Authors: Prasad V, Klöppel G, Lupp A, Wirtz R, Kaemmerer D,

Keywords: Ileal NET, serotonin, radioprotector, PRRT, immunohistochemistry, TPH1,

#3262 Real-world effectiveness and serotonin reduction in patients with progressive neuroendocrine tumors and carcinoid syndrome receiving telotristat ethyl

Introduction: Clinical trials have demonstrated the efficacy and safety of telotristat ethyl (TE) treatment in combination with somatostatin analogues (SSAs) in patients with neuroendocrine tumors (NETs) and inadequately controlled carcinoid syndrome (CS) diarrhea. The TELEACE study was designed to evaluate the real-world effectiveness of TE in US clinical practice.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Liu E

Authors: Liu E, Giacalone S, Joish V, Dharba S, Yarkoni T,

Keywords: neuroendocrine tumor, carcinoid syndrome, telotristat ethyl, serotonin,